Fig. 6

αIL6 and RS504393 promote NK cell antitumor activity and repress MOC2 tumors more effectively when combined. A, F Schematic showing the timeline of experimental procedures. Male C57BL/6 mice at 6–8 weeks of age received intramucosal injection of 1.0 × 10⁶ MOC2 or TC-1 cells. When tumors were established (10 days after cell inoculation), mice were randomized to receive the treatment of IgG2 isotype, αIL6 (100 µg/mouse), RS504393 (6 mg/kg) or the combination of αIL6 and RS504393 (n = 5/group). B, C MOC2 tumor growth curve and weight in each treatment group. Representative tumors from C57BL/6 mice with indicated treatment are shown in the upper panel of (B). D, I Percent of CD161⁺ NK cells in MOC2 (D) or TC-1 (I) tumors treated with αIL6 and RS504393 alone or in combination. Representative images and quantitative data are shown in the left and right panels. E, K Percent of Ki67⁺ NK cells in MOC2 (E) or TC-1 (K) tumors treated with αIL6 and RS504393 alone or in combination. Representative images and quantitative data are shown in the left and right panels. G, H TC-1 tumor growth curve and weight in each treatment group. Representative tumors from C57BL/6 mice with indicated treatment are shown in the upper panel of (G). *p < 0.05; **p < 0.01; ns: not significant